BTIG Research Raises Paratek Pharmaceuticals Inc (PRTK) Price Target to $56.00
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) had its price objective hoisted by stock analysts at BTIG Research from $47.00 to $56.00 in a research report issued on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. BTIG Research’s price target would suggest a potential upside of 159.26% from the stock’s previous close.
PRTK has been the topic of several other reports. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 15th. Cantor Fitzgerald set a $28.00 price objective on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 13th. Guggenheim reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Monday, March 27th. Robert W. Baird reiterated a “positive” rating and issued a $40.00 price objective on shares of Paratek Pharmaceuticals in a research report on Monday, March 27th. Finally, Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Paratek Pharmaceuticals in a research report on Monday, April 3rd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $36.78.
Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 1.736% during mid-day trading on Tuesday, reaching $21.975. The company’s stock had a trading volume of 816,312 shares. Paratek Pharmaceuticals has a 52 week low of $9.80 and a 52 week high of $25.00. The company’s 50-day moving average price is $18.64 and its 200 day moving average price is $15.06. The firm’s market capitalization is $533.68 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Thursday, March 2nd. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.33) by $0.17. The firm earned $0.03 million during the quarter.
In other news, CFO Douglas W. Pagan sold 3,405 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $15.09, for a total value of $51,381.45. Following the transaction, the chief financial officer now owns 58,983 shares of the company’s stock, valued at approximately $890,053.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Michael Bigham sold 5,000 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $15.09, for a total transaction of $75,450.00. Following the completion of the transaction, the chairman now directly owns 99,970 shares in the company, valued at approximately $1,508,547.30. The disclosure for this sale can be found here. Insiders have sold a total of 11,511 shares of company stock worth $173,701 over the last 90 days. 2.00% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC boosted its position in shares of Paratek Pharmaceuticals by 1.1% in the fourth quarter. Teachers Advisors LLC now owns 25,363 shares of the specialty pharmaceutical company’s stock valued at $391,000 after buying an additional 270 shares in the last quarter. Norges Bank purchased a new position in Paratek Pharmaceuticals during the fourth quarter valued at $1,486,000. Senzar Asset Management LLC purchased a new position in Paratek Pharmaceuticals during the fourth quarter valued at $1,918,000. Ellington Management Group LLC purchased a new position in Paratek Pharmaceuticals during the fourth quarter valued at $179,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Paratek Pharmaceuticals during the fourth quarter valued at $158,000. 76.06% of the stock is currently owned by institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).
Receive News & Stock Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.